Noida (Uttar Pradesh) [India], January 4 (ANI/PRNewswire): Curadev Pharma has created a Clinical Advisory Group (CAG) comprising eminent oncologists to provide guidance in the design and execution of immune-oncology clinical trials with CRD3874, its lead non-nucleoside, allosteric small molecule STING agonist
NOIDA, UP, Jan 4: Curadev Pharma has created a Clinical Advisory Group (CAG) comprising eminent oncologists to provide guidance in the design and execution of immune-oncology clinical trials with CRD3874, its lead non-nucleoside, allosteric small molecule STING agonist. Curadev recently received permission from the US FDA to commence FIH trials with systemically administered CRD3874 in patients with advanced/metastatic solid cancers. Dr Arjun Surya, CEO and CSO of Curadev said that, “We are honored to work with such an esteemed group […]